CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects.

Inspired by advances in cancer therapy, a team at the Buck Institute has engineered immune cells equipped with specialized targeting devices called chimeric antigen receptors (CARs) that can ...

Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a ...

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and ...

May 2025 marked another key milestone for Reacta Healthcare, as the first production run of pharmaceutical grade milk and egg ...

To assess T-cell-induced morphological changes, each organoid was segmented in the transmitted light (TL) channel using a ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...